NewsHK

Fidelity FHLC costs less than Invesco PBE for healthcare exposure

10/12/2026

The Fidelity MSCI Health Care Index ETF (FHLC) charges an expense ratio of 0.08%, a fraction of the 0.59% fee levied by the Invesco Biotechnology & Genome ETF (PBE).

This cost difference is central to the comparison between the two funds, which offer distinct levels of portfolio concentration and sector focus for investors seeking exposure to the healthcare industry.

FHLC provides broad exposure by tracking 365 holdings, with a 99% allocation to the healthcare sector and a 1% tilt toward technology.

The fund, launched in 2013, encompasses pharmaceuticals, equipment, and services providers. Its largest positions include Eli Lilly & Co. at 12.94%, Johnson & Johnson at 8.72%, and AbbVie at 6.57%.